Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences: mwb online Health Care ConferenceDate: July 1, 2025Presentation Time: 12 ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for Yesafili™ (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of ...

The Supervisory Board of AS Harju Elekter Group decided to increase the share capital of the company by 17,010 euros by issuing new ordinary shares. The increase in the share capital is due to the need to issue new shares to the management board members and key personnel of Harju Elekter and its subsidiaries participating in the option program approved with the resolution of the general meeting on 29 April 2021. A total of 4 current and former employees of Harju Elekter participated in the share issue relat ...

Core Viewpoint - Kymera Therapeutics, Inc. has announced a public offering of $250.8 million in common stock and pre-funded warrants to advance its pipeline of oral small molecule degrader medicines for immunological diseases [1][2]. Group 1: Offering Details - Kymera is selling 5,044,500 shares of common stock at a price of $44.00 per share and pre-funded warrants to purchase 655,500 shares at $43.9999 each [1]. - The gross proceeds from the offering are expected to be approximately $250.8 million, before deducting underwriting discounts and commissions [1]. - The underwriters have a 30-day option to purchase up to an additional 855,000 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance Kymera's pipeline of preclinical and clinical degrader programs, as well as for working capital and other general corporate purposes [2]. Group 3: Company Background - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative medicines for significant health issues [6]. - The company aims to provide a new generation of effective therapies for patients with immunological diseases [6].

Core Viewpoint - Achieve Life Sciences, Inc. is conducting a public offering of 15 million shares of common stock and accompanying warrants at a price of $3.00 per share, aiming to raise approximately $45 million to support the development of cytisinicline for nicotine dependence treatment [1][4]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence and smoking cessation [7]. - The company submitted a New Drug Application to the FDA for cytisinicline in June 2025, based on successful Phase 3 studies and an open-label safety study [7]. Offering Details - The public offering includes 15 million shares and warrants, with an additional 2.25 million shares available for underwriters to purchase [1][3]. - Each common warrant can be exercised for common stock at $3.00 or for pre-funded warrants at $2.999, expiring five years from issuance [2]. Financial Aspects - The gross proceeds from the offering are expected to be around $45 million, which will be used for advancing cytisinicline towards FDA approval and for general corporate purposes [4]. - The offering is expected to close around June 30, 2025, pending customary closing conditions [3]. Market Context - There are approximately 29 million adult smokers in the U.S., with tobacco use being the leading cause of preventable death [8]. - Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address the need for effective treatments for nicotine e-cigarette cessation, as there are currently no FDA-approved options for this indication [9].

Core Viewpoint - The California Court of Appeals upheld a previous ruling regarding Tejon Ranch Company's Centennial development, affirming that the company prevailed on 20 out of 23 trial court items, while the company plans to collaborate with Los Angeles County to advance the project for regional benefit and shareholder value [2][3]. Company Overview - Tejon Ranch Co. is a diversified real estate development and agribusiness company with a principal asset of 270,000 acres located approximately 60 miles north of Los Angeles and 30 miles south of Bakersfield [5]. Centennial Development - Centennial at Tejon Ranch is a proposed master-planned, mixed-use community covering approximately 12,000 acres, designed to be one of California's most sustainable communities, with plans for up to 19,333 homes, including over 3,000 affordable units [6]. - The development aims to address urgent needs for housing, jobs, and open space preservation in Los Angeles County [3][4]. Strategic Positioning - The company has a long history of navigating California's complex land use processes and expresses confidence in advancing the Centennial project to generate value for shareholders while providing housing and job opportunities [4].

Core Viewpoint - Acceleware Ltd. has entered into the Marwayne Agreement with O'Neill Industries International-Canada Inc., facilitating the transfer of certain assets and wells in Marwayne, Alberta, which aims to enhance cash flow and support the commercialization of its RF XL 2.0 technology [1][2]. Group 1: Agreement Details - The Marwayne Agreement involves Acceleware transferring its interests in existing wells, production equipment, leases, and licenses to O'Neill Canada for cash, assumption of liabilities, and a 5% gross overriding royalty (GORR) on future production for 12 months, with an estimated net benefit of $460,000 to Acceleware [8]. - Acceleware retains ownership of all RF XL heating and related equipment at Marwayne, including the Clean Tech Inverter (CTI) [8]. - A new farmout agreement is to be established within 90 days, allowing Acceleware to drill new RF XL 2.0 compliant test wells over the next five years [8]. Group 2: Strategic Intent - The agreement is part of Acceleware's strategy to transition from a research and development focus to a cash flow-generating enterprise, with the potential for future multi-well deployments of RF XL 2.0 at Marwayne [2]. - O'Neill Canada has been producing heavy oil at Marwayne and plans to increase production volumes through cold flow and thermal recovery techniques, indicating a mutually beneficial arrangement [3][10]. Group 3: Company Background - Acceleware is an advanced electromagnetic heating company specializing in radio frequency power-to-heat solutions aimed at decarbonizing industrial processes while reducing costs [4]. - The company is actively developing its patented RF XL technology, which is a low-cost, low-carbon thermal enhanced oil production method distinct from existing recovery techniques [6].

Core Viewpoint - Cygnus Metals Limited has successfully completed Tranche 1 of its Placement, raising A$18.2 million through the issuance of 211,627,907 fully paid ordinary shares at A$0.086 each, while also planning further share issuance under Tranche 2, subject to shareholder approval [1][2]. Group 1: Placement Details - The total amount raised in Tranche 1 is A$18,200,000 before costs, with shares issued under ASX Listing Rules 7.1 and 7.1A [1]. - A further 1,162,790 shares are intended to be issued under Tranche 2 to Non-Executive Director Raymond Shorrocks, pending shareholder approval at a general meeting in August 2025 [2]. Group 2: Company Operations - Cygnus Metals is engaged in ongoing exploration and drilling programs at its Chibougamau Copper-Gold Project in Quebec, with assay results pending from the current drill program [3]. - The company has a diversified portfolio, including lithium assets in the James Bay district and REE and base metal projects in Western Australia, aiming to drive resource growth and develop a hub-and-spoke operation model [6]. Group 3: Compliance and Disclosure - The shares were issued without disclosure under section 708A(5) of the Corporations Act 2001, and the company has complied with relevant provisions of the Act [3][7]. - The company confirms that there is no excluded information that needs to be disclosed under section 708A(6)(e) of the Act [7].

Core Points - Fortuna Mining Corp. held its 2025 annual general meeting of shareholders, with 188,888,907 common shares represented, accounting for 61.54% of the total issued and outstanding shares [2] - Shareholders voted in favor of all business matters, including the appointment of auditors and the election of all director nominees listed in the Management Information Circular dated May 1, 2025 [2] Voting Results - Jorge A. Ganoza received 159,475,985 votes (99.48% for) with 831,198 votes withheld (0.52%) [2] - David Laing received 154,870,542 votes (96.61% for) with 5,436,641 votes withheld (3.39%) [2] - Mario Szotlender received 154,344,778 votes (96.28% for) with 5,962,405 votes withheld (3.72%) [2] - David Farrell received 148,807,290 votes (92.83% for) with 11,499,893 votes withheld (7.17%) [2] - Alfredo Sillau received 158,876,299 votes (99.11% for) with 1,430,884 votes withheld (0.89%) [2] - Kylie Dickson received 159,252,340 votes (99.34% for) with 1,054,844 votes withheld (0.66%) [2] - Kate Harcourt received 159,513,569 votes (99.50% for) with 793,615 votes withheld (0.50%) [2] - Salma Seetaroo received 159,228,957 votes (99.33% for) with 1,078,227 votes withheld (0.67%) [2] Company Overview - Fortuna Mining Corp. is a Canadian precious metals mining company with operations in Argentina, Côte d'Ivoire, Mexico, and Peru, and exploration activities including the Diamba Sud Gold Project in Senegal [3] - The company focuses on sustainability, producing gold and silver while generating long-term shared value for stakeholders through efficient production, environmental protection, and social responsibility [3]

Tiburon, CA, June 26, 2025 (GLOBE NEWSWIRE) -- FIGX Capital Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 13,100,000 units. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading tomorrow, June 27, 2025, under the ticker symbol “FIGXU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share ...